Invention Grant
- Patent Title: In situ determination of acceptable resuspension in pharmaceutical products using water proton NMR
-
Application No.: US18170114Application Date: 2023-02-16
-
Publication No.: US12061160B2Publication Date: 2024-08-13
- Inventor: Yihua (Bruce) Yu , Marc Taraban , Christopher Fox
- Applicant: UNIVERSITY OF MARYLAND, BALTIMORE , ACCESS TO ADVANCED HEALTH INSTITUTE
- Applicant Address: US MD Baltimore
- Assignee: UNIVERSITY OF MARYLAND, BALTIMORE,ACCESS TO ADVANCED HEALTH INSTITUTE
- Current Assignee: UNIVERSITY OF MARYLAND, BALTIMORE,ACCESS TO ADVANCED HEALTH INSTITUTE
- Current Assignee Address: US MD Baltimore; US WA Seattle
- Agency: Casimir Jones SC
- Agent Tristan A. Fuierer
- The original application number of the division: US16593145 2019.10.04
- Main IPC: G01N24/08
- IPC: G01N24/08 ; G01N33/15

Abstract:
A method of using the transverse relaxation rate (R2) of solvent NMR signal to noninvasively assess if an alum-containing product, such as a vaccine, has been acceptably resuspended for use following transport and/or storage. This technique allows for the manufacturer and/or distributor and/or end user to monitor for unexpected stressors associated with transport and/or storage including, but not limited to, temperature fluctuations, pH changes, vigorous shaking during transportation, exposure to sunlight, and freezing.
Public/Granted literature
Information query